That’s a wrap

That’s a wrap

Well another JPM in the books and it’s time to look back. There are some companies presenting today but let’s face facts if JPM puts you in a Thursday time slot the needle is not pointing in the right direction. Which is likely why MannKind (NASDAQ: MNKD) is scheduled for today at 10 am. There is really no need to hear what MannKind has to say as the story is well known and isn’t going to change anytime soon. Yes, they have enough money now to fight on another day but all the money in the world will not put humpty dumpty back together again.

Ok by now everyone should know that Intarcia was the biggest winner here, this is a company that will get a bigger room and a prime Monday time slot next year.  Anyone who watched the TV show the Jefferson’s Intarcia like the Jefferson’s is moving on up.

Dexcom (NASDAQ: DXCM) was another winner here as analysts are finally learning not freak out when there is a bump in the road. The analysts who follow Dexcom remind us of Chicago Blackhawks fans who freak anytime the team loses a few games during what is basically a meaningless regular season. The Hawks are one the best teams in the NHL, a team with great talent and outstanding leadership, same with Dexcom. The Hawks like Dexcom aren’t built for the regular season, they are built to win Stanley Cups, something they have done three time is the last seven years.

Although it’s not because of what they said here Medtronic (NYSE: MDT) was also a big winner. Not like the company needed any more good fortune but with Tandem (NASDAQ: TNDM) imploding, Animas going nowhere and Insulet (NASDAQ: PODD) being Insulet it’s as if the opposing teams have fumbled on their own one yard and all Medtronic has to do is pick up the ball and walk it into the end zone.

We are really trying to say something nice about our wine drinking friends from France but as Momma Kliff used to say; “When you don’t have something nice to say, stay silent.” So, let’s move on.

It would be an over statement to say IBM Watson Health was a winner. A better way of looking at them, like Teladoc, is their strategies and success to date validate much of what we have been saying for years. Big data and whiz bang technology will forever change not just how diabetes is managed but how diabetes products and services are delivered to the patient. The days when the physician was king of the mountain are coming to an end, this does not by any means mean that physicians will be taken out of the loop. Rather what it means is the role they play will be more consultative in the future.

As we leave this beautiful albeit very wet city by the bay, we wonder which of the conventional BGM companies will be here next year. Or perhaps a better way of thinking is since they likely will be here what will they be saying. Johnson and Johnson (NYSE: JNJ), Roche and Abbott (NYSE: ABT) know this business is dying and nothing will change that. Abbott thanks to Libre still has a chance in glucose monitoring but JNJ and Roche are dead ducks.

Thanks again to all the wonderful people at JPM as they put on one hell of a conference. And kudos to the staff at the Westin St. Francis for being so nice and accommodating, let’s be honest not easy dealing with the crowds and they did it very well. And of course, thanks to this beautiful city by the bay all we ask is that next year we go back to some good weather all this rain was nuts. Safe travels everyone, see you next year.